20231109-华创证券-华创医疗器械随笔系列1_阿尔兹海默症诊断专题_治疗手段突破催化诊断行业变革_24页_2mb

Alzheimer's Disease Diagnosis and Treatment Breakthroughs Summary

This report analyzes the relationship between advancements in Alzheimer's Disease (AD) treatment and their impact on the diagnostic industry. AD is a progressive neurodegenerative disorder characterized by cognitive decline and behavioral symptoms, with pathology involving amyloid-beta plaques and tau protein tangles. Current diagnosis faces challenges due to delayed detection, often relying on late-stage symptoms, with gold standards including amyloid-PET and CSF biomarker testing. Emerging treatments, such as Lecanemab and Donanemab, target early stages, stimulating demand for earlier diagnosis. Blood-based diagnostics are emerging as a cost-effective, less invasive alternative, with potential to improve diagnostic efficiency and reduce wait times. The global AD patient base is large and growing, driven by aging populations, with China projected to have significant numbers by 2030.

Treatment breakthroughs, including FDA-approved drugs like Aducanumab, Lecanemab, and Donanemab, have catalyzed changes in the diagnostic landscape. Lecanemab and Donanemab are designed for early-stage patients (MCI or mild dementia), necessitating broader diagnostic access. This has led to policies supporting expanded insurance coverage for diagnoses, potentially increasing demand. Blood-based biomarkers, supported by guidelines like NIA-AA, offer improved accessibility and are expected to integrate into clinical workflows, reducing reliance on costly imaging and invasive CSF tests.

Epidemiological data highlights a rising burden: globally, AD affects around 55 million people, with China's cases expected to surge due to aging. In China, annual AD diagnosis needs could reach millions, driving market growth. Blood-based AD diagnosis is poised to expand, with estimates suggesting a market size of up to 18.7 billion yuan by 2030 in China. Investment opportunities include companies like East China Pharma (Tau-PET agents), AtomHi-Kang (Aβ-PET development), and diagnostics firms such as Norozyan and JinYi Medical, which are advancing blood tests.

However, risks exist, including uncertainties in treatment adoption, regulatory delays, and intense competition. If these challenges are addressed, the diagnostic industry could transform, offering more timely and efficient AD detection, ultimately benefiting patient outcomes.

Key Statistics and Predictions

• Global AD patients: Approximately 55 million, expected growth to 139 million by 2050.
• China's AD cases: 983,000 in 2022, projected to exceed 20 million by 2040.
• AD blood diagnosis market in China: Forecast to reach 18.7 billion yuan (around $2.6 billion) by 2030.
• AD blood test benefits: Potential to reduce diagnostic wait times from years to months.

Investment and Market Outlook

Companies with AD-related diagnostics and drug development potential include East China Pharma, AtomHi-Kang, Norozyan, and diagnostics providers like JinYi Medical and Beijing Fosun Pharmaceutical.

• East China Pharma has exclusive rights for Tau-PET agents.
• AtomHi-Kang is advancing Aβ-PET and has clinical trials underway.
• Diagnostics firms are innovating blood tests, with some already approved in Europe or China.
• Growth driven by increasing diagnosis demand from treatments and aging populations, enhancing market accessibility and profitability.

Risks and Disclaimers

Potential risks include delayed treatment approvals, adoption challenges for blood diagnostics, market competition, and pricing pressures. The analysis assumes continued innovation but notes uncertainties in real-world application. Investors should monitor regulatory updates and clinical trial results for informed decisions.